首页> 美国卫生研究院文献>Patient preference and adherence >Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement
【2h】

Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement

机译:心脏十字路口:决定机械或生物人工心脏瓣膜的更换

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nearly 15 million people in the United States suffer from either aortic or mitral valvular disease. For patients with severe and symptomatic valvular heart disease, valve replacement surgery improves morbidity and mortality outcomes. In 2009, 90,000 valve replacement surgeries were performed in the United States. This review evaluates the advantages and disadvantages of mechanical and bioprosthetic prosthetic heart valves as well as the factors for consideration in deciding the appropriate valve type for an individual patient. Although many caveats exist, the general recommendation is for patients younger than 60 to 65 years to receive mechanical valves due to the valve’s longer durability and for patients older than 60 to 65 years to receive a bioprosthetic valve to avoid complications with anticoagulants. Situations that warrant special consideration include patient co-morbidities, the need for anticoagulation, and the potential for pregnancy. Once these characteristics have been considered, patients’ values, anxieties, and expectations for their lifestyle and quality of life should be incorporated into final valve selection. Decision aids can be useful in integrating preferences in the valve decision. Finally, future directions in valve technology, anticoagulation, and medical decision-making are discussed.
机译:在美国,近1500万人患有主动脉或二尖瓣疾病。对于患有严重和症状性瓣膜性心脏病的患者,瓣膜置换手术可改善发病率和死亡率。 2009年,在美国进行了90,000例瓣膜置换手术。这篇综述评估了机械和生物假体心脏瓣膜的优缺点,以及在确定适合单个患者的瓣膜类型时要考虑的因素。尽管存在许多警告,但一般建议还是建议年龄在60至65岁之间的患者接受机械瓣膜,因为该阀具有更长的耐用性,并且建议年龄超过60至65岁的患者应使用生物人工瓣膜以避免抗凝剂并发症。需要特别考虑的情况包括患者合并症,抗凝治疗的必要性和怀孕的可能性。一旦考虑了这些特征,就应将患者的价值观,焦虑以及对其生活方式和生活质量的期望纳入最终的瓣膜选择中。决策辅助在将偏好整合到阀门决策中时可能很有用。最后,讨论了瓣膜技术,抗凝和医学决策的未来方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号